Adnan Rafiq, MD
Internal Medicine · Houston, TXNPI 1831352269
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 758 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 54 manufacturers, the largest accounting for just 12.7% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 758 payments — averaging $17.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$2K
- GSK$2K
- AstraZeneca$1K
- Lilly USA, LLC$959
- Merz North America, Inc.$864
- plus $5K from 48 others
Across 26 payments — averaging $8363.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Redhill Biopharma Inc.$108K
- Takeda Pharmaceuticals U.S.A., Inc.$103K
- Veru Inc.$7K
What the payments were for
- Food & beverage$12,90499%
- Education$1181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$696
- DISEASE STATE$125
- FARXIGA$107
- SYMBICORT$107
- BREZTRI AEROSPHERE$107
How this compares
$13,022 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 233 | $317,517 |
| MounjaroTirzepatide | 148 | $184,583 |
| JardianceEmpagliflozin | 85 | $111,888 |
| JanuviaSitagliptin Phosphate | 36 | $53,414 |
| EliquisApixaban | 42 | $51,083 |
| RybelsusSemaglutide | 27 | $42,150 |
| MyrbetriqMirabegron | 35 | $32,199 |
| FarxigaDapagliflozin Propanediol | 23 | $28,225 |
| TradjentaLinagliptin | 17 | $26,596 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $25,793 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $20,552 |
| LinzessLinaclotide | 18 | $18,032 |
| Aimovig AutoinjectorErenumab-Aooe | 14 | $14,078 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $13,428 |
| XareltoRivaroxaban | 14 | $12,237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,579 | $359,667260 claims |
| Lilly USA, LLCMounjaro | $959 | $184,583148 claims |
| Boehringer IngelheimJardiance, Tradjenta | $70 | $138,485102 claims |
| MerckJanuvia | $64 | $53,41436 claims |
| PfizerEliquis | $399 | $51,08342 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort | $1,049 | $38,37847 claims |
| Astellas Pharma US IncMyrbetriq | $336 | $32,19935 claims |
| GSKTrelegy Ellipta | $1,508 | $25,79330 claims |
| AbbVieLinzess, Restasis | $1,660 | $24,86331 claims |
| Johnson & JohnsonXarelto | $128 | $12,23714 claims |
| Cequr CorporationCequr Simplicity | $87 | $11,39911 claims |
| Sanofi-aventis U.S. LLCLantus | $459 | $3,62624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Hussein TawbiHouston$365K
- Hans LeeHouston$327K
- Tapan KadiaHouston$311K
- Nitin JainHouston$281K
- Krina PatelHouston$255K
- Nicholas ShortHouston$247K
- Naveen PemmarajuHouston$230K
- Mariana Chavez MacgregorHouston$188K
- Shumei KatoHouston$180K
- Sukhdeep BasraHouston$168K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.